The Patent Finder

Clinigen Group PLC

Also on record
Records under this name other than the patents Clinigen Group PLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Back to Clinigen Group PLC

PatentTitleStatus Expires Confidence
US 7,906,515Cancer treatment with topoisomerase-II inhibitor, a bis-dioxypiperazine and radiation
Term ended
Term ended Mar 2, 2025 · From the USPTO record
Term endedTerm ended Mar 2, 2025From the USPTO record
US 7,053,072Methods for the Administration of Amifostine and Related Compounds
Term ended
Term ended Nov 5, 2022 · High confidence
Term endedTerm ended Nov 5, 2022High confidence
US 7,678,779Methods for the Administration of Amifostine and Related Compounds
Term ended
Term ended May 31, 2022 · High confidence
Term endedTerm ended May 31, 2022High confidence
US 7,368,440Methods for the Administration of Amifostine and Related Compounds
Term ended
Term ended May 8, 2022 · High confidence
Term endedTerm ended May 8, 2022High confidence
US 6,218,377Methods for the administration of amifostine and related compounds
Term ended
Term ended Jun 5, 2020 · From the USPTO record
Term endedTerm ended Jun 5, 2020From the USPTO record
US 6,727,253Treatment of accidental extravasation of anthracyclines
Term ended
Term ended Mar 13, 2020 · From the USPTO record
Term endedTerm ended Mar 13, 2020From the USPTO record
US 6,753,323Topical Administration of Amifostine and Related Compounds
Term ended
Term ended Sep 27, 2019 · Medium confidence
Term endedTerm ended Sep 27, 2019Medium confidence
US 7,151,094Topical Administration of Amifostine and Related Compounds
Term ended
Term ended Sep 15, 2019 · Medium confidence
Term endedTerm ended Sep 15, 2019Medium confidence
US 6,239,119Topical administration of amifostine and related compounds
Term ended
Term ended Apr 26, 2019 · From the USPTO record
Term endedTerm ended Apr 26, 2019From the USPTO record
US 6,265,385Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy
Term ended
Term ended Mar 8, 2019 · From the USPTO record
Term endedTerm ended Mar 8, 2019From the USPTO record
10 of 21 patents shown.
Pro members see all 21.
Pro members: see all 21 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited